These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 26229114)

  • 1. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.
    Williams WB; Liao HX; Moody MA; Kepler TB; Alam SM; Gao F; Wiehe K; Trama AM; Jones K; Zhang R; Song H; Marshall DJ; Whitesides JF; Sawatzki K; Hua A; Liu P; Tay MZ; Seaton KE; Shen X; Foulger A; Lloyd KE; Parks R; Pollara J; Ferrari G; Yu JS; Vandergrift N; Montefiori DC; Sobieszczyk ME; Hammer S; Karuna S; Gilbert P; Grove D; Grunenberg N; McElrath MJ; Mascola JR; Koup RA; Corey L; Nabel GJ; Morgan C; Churchyard G; Maenza J; Keefer M; Graham BS; Baden LR; Tomaras GD; Haynes BF
    Science; 2015 Aug; 349(6249):aab1253. PubMed ID: 26229114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques.
    Han Q; Williams WB; Saunders KO; Seaton KE; Wiehe KJ; Vandergrift N; Von Holle TA; Trama AM; Parks RJ; Luo K; Gurley TC; Kepler TB; Marshall DJ; Montefiori DC; Sutherland LL; Alam MS; Whitesides JF; Bowman CM; Permar SR; Graham BS; Mascola JR; Seed PC; Van Rompay KKA; Tomaras GD; Moody MA; Haynes BF
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
    Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
    Front Immunol; 2020; 11():719. PubMed ID: 32411138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactivity of HIV vaccine responses and the microbiome.
    Williams WB; Han Q; Haynes BF
    Curr Opin HIV AIDS; 2018 Jan; 13(1):9-14. PubMed ID: 29035947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.
    Moody MA; Yates NL; Amos JD; Drinker MS; Eudailey JA; Gurley TC; Marshall DJ; Whitesides JF; Chen X; Foulger A; Yu JS; Zhang R; Meyerhoff RR; Parks R; Scull JC; Wang L; Vandergrift NA; Pickeral J; Pollara J; Kelsoe G; Alam SM; Ferrari G; Montefiori DC; Voss G; Liao HX; Tomaras GD; Haynes BF
    J Virol; 2012 Jul; 86(14):7496-507. PubMed ID: 22553329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 7. Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women.
    Sacha CR; Vandergrift N; Jeffries TL; McGuire E; Fouda GG; Liebl B; Marshall DJ; Gurley TC; Stiegel L; Whitesides JF; Friedman J; Badiabo A; Foulger A; Yates NL; Tomaras GD; Kepler TB; Liao HX; Haynes BF; Moody MA; Permar SR
    Mucosal Immunol; 2015 Mar; 8(2):316-26. PubMed ID: 25100291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
    J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV vaccine design and the neutralizing antibody problem.
    Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
    Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
    [No Abstract]   [Full Text] [Related]  

  • 11. B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates.
    Ota T; Doyle-Cooper C; Cooper AB; Doores KJ; Aoki-Ota M; Le K; Schief WR; Wyatt RT; Burton DR; Nemazee D
    J Immunol; 2013 Sep; 191(6):3179-85. PubMed ID: 23940273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
    Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
    J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.
    Trama AM; Moody MA; Alam SM; Jaeger FH; Lockwood B; Parks R; Lloyd KE; Stolarchuk C; Scearce R; Foulger A; Marshall DJ; Whitesides JF; Jeffries TL; Wiehe K; Morris L; Lambson B; Soderberg K; Hwang KK; Tomaras GD; Vandergrift N; Jackson KJL; Roskin KM; Boyd SD; Kepler TB; Liao HX; Haynes BF
    Cell Host Microbe; 2014 Aug; 16(2):215-226. PubMed ID: 25121750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.
    Cram JA; Fiore-Gartland AJ; Srinivasan S; Karuna S; Pantaleo G; Tomaras GD; Fredricks DN; Kublin JG
    PLoS One; 2019; 14(12):e0225622. PubMed ID: 31869338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
    Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
    Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses against a new HIV-1 p24-gp41/pCAGGS-IL-12 DNA vaccine in Balb/c mice.
    Roodbari F; Sabahi F; Sarbolouki MN; Barkhordari F; Adeli A; Jamedar A; Mahboudi F
    Iran J Immunol; 2012 Jun; 9(2):86-97. PubMed ID: 22735796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
    Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
    Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated.
    Liao HX; Chen X; Munshaw S; Zhang R; Marshall DJ; Vandergrift N; Whitesides JF; Lu X; Yu JS; Hwang KK; Gao F; Markowitz M; Heath SL; Bar KJ; Goepfert PA; Montefiori DC; Shaw GC; Alam SM; Margolis DM; Denny TN; Boyd SD; Marshal E; Egholm M; Simen BB; Hanczaruk B; Fire AZ; Voss G; Kelsoe G; Tomaras GD; Moody MA; Kepler TB; Haynes BF
    J Exp Med; 2011 Oct; 208(11):2237-49. PubMed ID: 21987658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.